AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 31909554
Drug: 300 g/l
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 g/l PEG (drought stress)
Trial: 28012633
Drug: Dexamethasone (4mg/ml,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (4mg/ml, 1ml) administered 15min before surgery
Trial: 28012633
Drug: Dexamethasone (4mg/ml,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (4mg/ml, 1ml) administered 15min after surgery
Trial: 28012633
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered 15min before and after surgery
Trial: 24555998
Drug: HBV envelope‐expressing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HBV envelope‐expressing DNA vaccine (5 intramuscular injections at weeks 0, 8, 16, 40, and 44)
Trial: 24555998
Drug: HBV envelope‐expressing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HBV envelope‐expressing DNA vaccine
Trial: 19358927
Drug: crocetin (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: crocetin (15 mg)
Trial: 19358927
Drug: ascorbic acid
RxNorm normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ascorbic acid (3,000 mg)
Trial: 12585168
Drug: Colquhounia root
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colquhounia root tablet (CRT)
Trial: 12585168
Drug: Hormone or
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormone or cytotoxic medicine (Control)
Trial: 9584030
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg of methadone with 5 visits per week
Trial: 9584030
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg of methadone with fewer visits
Trial: 9584030
Drug: 80 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg of methadone
Trial: 2647605
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of porcine GIP (2 pmol.kg‐1.min‐1)
Trial: 352210
Drug: Inactivated bivalent
RxNorm normalized name: diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Tdvax]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactivated bivalent (A/NJ and A/Victoria) influenza vaccine
Trial: 28525512
Drug: Parecoxib (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parecoxib (40 mg at the end of surgery and then every 12 hours for 3 days)
Trial: 19096945
Drug: Subcutaneous injection
RxNorm normalized name: EPINEPHRINE 0.3 mg SUBCUTANEOUS INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection of sterile water
Trial: 15504182
Drug: Hyperbaric bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperbaric bupivacaine 7.5 mg with sufentanil 5 microg
Trial: 15504182
Drug: Hyperbaric bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperbaric bupivacaine 15 mg
Trial: 9259608
Drug: Immunochemical method
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunochemical method (ELISA) for detecting P. carinii antibodies
Trial: 30972018
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg fasudil
Trial: 30972018
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg fasudil
Trial: 30972018
Drug: Fasudil (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fasudil (30 mg or 60 mg)
Trial: 30049304
Drug: Desmopressin oral
RxNorm normalized name: desmopressin Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desmopressin oral tablet (0.6 mg; 0.2 mg × 3) under fed conditions
Trial: 30049304
Drug: Desmopressin oral
RxNorm normalized name: desmopressin Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desmopressin oral tablet (0.6 mg; 0.2 mg × 3) under fasted conditions
Trial: 19914369
Drug: EG 500
RxNorm normalized name: Prosys Leg 500 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EG 500 (500 mg of Campomanesia xanthocarpa)
Trial: 19914369
Drug: EG 250
RxNorm normalized name: Gris-PEG 250mg Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EG 250 (250 mg of Campomanesia xanthocarpa)
Trial: 19914369
Drug: CG (placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CG (placebo capsules)
Trial: 10066008
Drug: Placebo medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo medication plus exposure
Trial: 8952328
Drug: Improved Estimated
RxNorm normalized name: Improvest
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Improved Estimated Ecological Daily Intake (EEDI) method for estimating daily intake of food contaminants and additives.
Trial: 8952328
Drug: Improved EEDI
RxNorm normalized name: Improvest
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Improved EEDI method for estimating daily intake of environmental contaminants.
Trial: 6478471
Drug: Acebutolol, 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acebutolol, 50 mg
Trial: 6478471
Drug: Propranolol, 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol, 10 mg
Trial: 28760152
Drug: S-1 maintenance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-1 maintenance therapy
Trial: 30101439
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg TFV film
Trial: 30101439
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg TFV film
Trial: 30101439
Drug: TFV 1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TFV 1% gel
Trial: 23006462
Drug: Medical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical treatment for a variable period of 1-12 years
Trial: 19947406
Drug: Short-wave therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short-wave therapy included in rehabilitative program
Trial: 17179770
Drug: N-3 polyunsaturated
RxNorm normalized name: Omega-3 (n-3) polyunsaturated fatty acids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N-3 polyunsaturated fatty acids (PUFAs) - 2 capsules containing 1 g of fish oil 3 times daily (n = 60)
Trial: 17179770
Drug: Placebo -
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo - 1 g of paraffin oil capsules (n = 62)
Trial: 17179770
Drug: N-3 polyunsaturated
RxNorm normalized name: Omega-3 (n-3) polyunsaturated fatty acids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N-3 polyunsaturated fatty acids (PUFAs) - patients with baseline TG levels >10 g/L
Trial: 15123223
Drug: Salmeterol/fluticasone propionate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salmeterol/fluticasone propionate (SLM/FP) 50 microg and 500 microg Diskus, 1 inhalation twice daily
Trial: 15123223
Drug: Theophylline (THEO)
RxNorm normalized name: Theophylline
DrugBank: Theophylline (DB00277)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Theophylline (THEO) plus fluticasone propionate (FP) 500 microg Diskus, 1 inhalation twice daily
Trial: 9678714
Drug: High-dose methylprednisolone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose methylprednisolone (HDMP, 900-600 mg/m2 orally)
Trial: 9678714
Drug: Conventional-dose prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conventional-dose prednisolone (2 mg/kg/day orally)
Trial: 28000311
Drug: Subcutaneous immunoglobulin
RxNorm normalized name: immunoglobulin A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous immunoglobulin (SCIG) 0.4 g/kg/week for 5 weeks
Trial: 21745374
Drug: Intravenous immunoglobulin
RxNorm normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous immunoglobulin (IVIG) 0.4 g/kg/day for 5 days
Trial: 26555352
Drug: High-dose intradermal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose intradermal TIV
Trial: 12054149
Drug: Sublingual fentanyl
RxNorm normalized name: fentanyl Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual fentanyl citrate (SLFC)
Trial: 11326965
Drug: NO inhalation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NO inhalation (10 ppm for 30 min)
Trial: 11326965
Drug: Nifedipine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine (10 mg, tid) in addition to conventional therapy
Trial: 11326965
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy (oxygen, intravenous furosemide, aminophylline, dexamethasone)
Trial: 7827638
Drug: Transdermal E2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal E2 (0.05 mg/24 h)
Trial: 7827638
Drug: Transdermal E2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal E2 (0.05 mg/24 h) + Nomegestrol acetate (5 mg/24 h)
Trial: 7827638
Drug: E2 treatment
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: E2 treatment (after 2 weeks)
Trial: 7827638
Drug: E2 treatment
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: E2 treatment (3rd month)
Trial: 3287675
Drug: Aspirin 300
RxNorm normalized name: aspirin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 300 mg or 1,200 mg daily for a mean duration of 35 months
Trial: 3287675
Drug: Placebo (not
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (not taking aspirin)
Trial: 30303905
Drug: Torsemide 20
RxNorm normalized name: torsemide 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Torsemide 20 mg/d for 5 days
Trial: 26049866
Drug: 250 mg
RxNorm normalized name: rutin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg cranberry powder (Flowens™)
Trial: 26049866
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg cranberry powder (Flowens™)
Trial: 17347010
Drug: Before GH
RxNorm normalized name: FUSION PROTEIN OF HUMAN CHORIOGONADOTROPIN SUBUNIT .BETA. (CG- .BETA.)-(118-145)-PEPTIDE (1-28) WITH HUMAN SOMATOTROPIN (GROWTH HORMONE, GH) (29-219) AND TWO TANDEM COPIES OF HUMAN CHORIOGONADOTROPIN SUBUNIT .BETA. (CG-.BETA.)-(118-145)- PEPTIDE (220-247
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Before GH replacement therapy
Trial: 17347010
Drug: During GH
RxNorm normalized name: FUSION PROTEIN OF HUMAN CHORIOGONADOTROPIN SUBUNIT .BETA. (CG- .BETA.)-(118-145)-PEPTIDE (1-28) WITH HUMAN SOMATOTROPIN (GROWTH HORMONE, GH) (29-219) AND TWO TANDEM COPIES OF HUMAN CHORIOGONADOTROPIN SUBUNIT .BETA. (CG-.BETA.)-(118-145)- PEPTIDE (220-247
FDA approved: no
EMA approved: no
PMDA approved: no
Description: During GH replacement therapy
Trial: 7544628
Drug: G-CSF administration
RxNorm normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-CSF administration starting on day 0 (group A)
Trial: 7544628
Drug: G-CSF administration
RxNorm normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-CSF administration starting on day +7 (group B)
Trial: 7544628
Drug: G-CSF administration
RxNorm normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-CSF administration (both groups)
Trial: 550376
Drug: 250 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 micrograms salbutamol (bolus intravenous injection)
Trial: 30661551
Drug: MATCH (modular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MATCH (modular evidence-based treatment)
Trial: 23370978
Drug: 4% lidocaine
RxNorm normalized name: Lidocaine 344 mg TOPICAL PATCH [Pain Relief 4% Lidocaine]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4% lidocaine spray
Trial: 20027938
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate cream (Cutivate)
Trial: 19839994
Drug: Risperidone 0.5-2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risperidone 0.5-2.5 mg/day
Trial: 19839994
Drug: Risperidone 3-6
RxNorm normalized name: risperidone 6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risperidone 3-6 mg/day
Trial: 15898029
Drug: Medial canthus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medial canthus single-injection peribulbar anesthesia
Trial: 15898029
Drug: Double-injection peribulbar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double-injection peribulbar anesthesia
Trial: 9615558
Drug: Standard care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard care plus daily OMT (10 to 20 minutes daily)
Trial: 7648588
Drug: Low osmolar
RxNorm normalized name: Watersoluble, nephrotropic, low osmolar X-ray contrast media
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low osmolar contrast material (Omnipaque 240 mgI/ml) (n = 33)
Trial: 338089
Drug: Prophylactic low
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic low dose subcutaneous calcium heparin (dose based on body weight)
Trial: 30157383
Drug: Bacteriophage treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bacteriophage treatment (15 mg capsule containing 4 strains of bacteriophages)
Trial: 27043237
Drug: Probiotics (Bacillus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotics (Bacillus subtilis and Enterococcus faecalis) 0.5 g three times daily through a nasogastric feeding tube plus standard preventive strategies
Trial: 12177541
Drug: 80 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg methylprednisolone acetate (Depomedrol)
Trial: 12177541
Drug: 2 mL
RxNorm normalized name: ethanol 2 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mL saline (control)
Trial: 10459686
Drug: Trazodone 100
RxNorm normalized name: traZODone 100 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trazodone 100 mg/day
Trial: 10459686
Drug: Trazodone (50-100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trazodone (50-100 mg/day)
Trial: 7776455
Drug: Ileal low
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ileal low pressure reservoir using the Goodwin cup‐patch principle combined with an afferent ileal tubular segment
Trial: 2772366
Drug: Propranolol (PPL)
DrugBank: Propranolol (DB00571)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propranolol (PPL) (160‐240 mg/day)
Trial: 2772366
Drug: Pindolol (PDL)
RxNorm normalized name: Pindolol
DrugBank: Pindolol (DB00960)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pindolol (PDL) and Clopamide (CLP) (PDL 10 mg, CLP 5 mg per tablet, 1-3 tablets based on blood pressure response)
Trial: 2772366
Drug: Hydrochlorothiazide (HCT)
RxNorm normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide (HCT) (150‐100 mg/day)
Trial: 342149
Drug: Zinc sulphate
RxNorm normalized name: Zinc sulphate
DrugBank: Zinc acetate (DB14487)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Zinc sulphate treatment
Trial: 30656648
Drug: Routine Fluid
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine Fluid Treatment (RFT)
Trial: 26944938
Drug: Prescription Interactive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prescription Interactive Voice Response (IVR) Talking Prescriptions (Talking Rx) and SMS reminders
Trial: 24566877
Drug: STOPP recommendations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: STOPP recommendations made by the inpatient geriatric consultation team (IGCT) to ward physicians to discontinue potentially inappropriate medications (PIMs)
Trial: 22894574
Drug: Tofacitinib 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tofacitinib 0.5 mg
Trial: 22460142
Drug: Tofacitinib 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tofacitinib 3 mg
Trial: 24030917
Drug: Tofacitinib 10
RxNorm normalized name: tofacitinib 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tofacitinib 10 mg
Trial: 23855761
Drug: Tofacitinib 15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tofacitinib 15 mg
Trial: 17692985
Drug: Pegylated‐interferon plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pegylated‐interferon plus ribavirin (800 mg/day up to 52 weeks)
Trial: 17692985
Drug: Genotype 1
RxNorm normalized name: dengue virus live antigen, CYD serotype 1 / dengue virus live antigen, CYD serotype 2 / dengue virus live antigen, CYD serotype 3 / dengue virus live antigen, CYD serotype 4 Injection [Dengvaxia]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Genotype 1 with low viral load at start of therapy
Trial: 15822043
Drug: Ulinastatin (150,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ulinastatin (150,000 U) administered by intravenous infusion for 10 minutes before ERCP
Trial: 15822043
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered by intravenous infusion for 10 minutes before ERCP
Trial: 9084463
Drug: CP-148,623 (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CP-148,623 (300 mg twice a day; n = 12)
Trial: 20002061
Drug: 50 g
RxNorm normalized name: glucose 50 g/296 mL oral liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 g activated charcoal
Trial: 31328363
Drug: GLP-1 antagonist
RxNorm normalized name: Arg34Lys26-(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1[7-37]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLP-1 antagonist exendin 9-39
Trial: 26154030
Drug: EXPL (1.61
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EXPL (1.61 g protein/100 kcal; modified bovine whey proteins with caseinoglycomacropeptide removed)
Trial: 26154030
Drug: CTRL (2.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CTRL (2.15 g protein/100 kcal; unmodified bovine milk protein with a whey/casein ratio of 60/40)
Trial: 12721161
Drug: Ovulation induction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ovulation induction (OI) with clomiphene (CC) or gonadotrophin (FSH) and intrauterine insemination (IUI)
Trial: 9416653
Drug: Neuroleptic dosage
RxNorm normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neuroleptic dosage reduction (tapered by 25% each month)
Trial: 31963802
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose (HD: 13 g of EAAS BID)
Trial: 31963802
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose (LD: 8 g of EAAS BID)
Trial: 29196046
Drug: Open-label intravenous
RxNorm normalized name: Ga-68-Labeled PSMA-11
DrugBank: Gallium Ga-68 gozetotide (DB16019)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Open-label intravenous ceftriaxone 2000 mg in addition to usual care
Trial: 12175665
Drug: Enoxaparin (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin (30 mg intravenous bolus and 1 mg/kg subcutaneous injections twice daily for 3-8 days)
Trial: 9635630
Drug: Leuprolide acetate
RxNorm normalized name: Leuprolide Acetate
DrugBank: Leuprolide (DB00007)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leuprolide acetate (both doses)
Trial: 7653805
Drug: Pancuronium 0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pancuronium 0.15 mg/kg
Trial: 31241007
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of nano‐curcumin (80 mg) plus CoQ10 (300 mg)
Trial: 31241007
Drug: Nano‐curcumin (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nano‐curcumin (80 mg)
Trial: 31241007
Drug: CoQ10 (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CoQ10 (300 mg)
Trial: 31241007
Drug: Control (nano‐curcumin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (nano‐curcumin and CoQ10 placebo included oral paraffin oil)
Trial: 29628182
Drug: Time In
RxNorm normalized name: Cleartime Indoor & Outdoor Allergies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Time In intervention (sensorimotor intervention combining biomechanical physiotherapeutic procedures and psychological strategies, 3h weekly sessions for 5 weeks)
Trial: 15711670
Drug: Interferon (IFN)
RxNorm normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon (IFN) alfa 2b 3 million units 3 times per week plus ribavirin 1000-1200 mg orally per day for 48 weeks
Trial: 7859421
Drug: Ceftriaxone 50
RxNorm normalized name: ceftriaxone 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftriaxone 50 mg/kg (single dose)
Trial: 7859421
Drug: Cefaclor 40
RxNorm normalized name: Cefaclor
DrugBank: Cefaclor (DB00833)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefaclor 40 mg/kg/day (10 days)
Trial: 2816761
Drug: Theophylline (7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theophylline (7 mg/kg)
Trial: 128475
Drug: Locacorten (0.02%)-Vioform
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Locacorten (0.02%)-Vioform (3%) cream
Trial: 26407753
Drug: Enoxaparin followed
RxNorm normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin followed by warfarin
Trial: 24902962
Drug: Oral pioglitazone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral pioglitazone 30 mg daily for 10 weeks
Trial: 23132643
Drug: Acidic saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acidic saline (2.5 mL, pH 3.3)
Trial: 23132643
Drug: Isotonic saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isotonic saline (2.5 mL, pH 6.0)
Trial: 11244441
Drug: Meningococcal polysaccharide
RxNorm normalized name: meningococcal polysaccharide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meningococcal polysaccharide (Men PS) vaccine, administered 8 months after BMT (early group; 22 patients)